SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3508 102 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Regeneron (REGN) is a biotech working in recombinant DNA technology. Until '94 it generally traded between 10 and 20 dollars until the FDA beat it up on it's treatment for Lou Gehrig's Disease. While it was trading at the $4 level at the end of '94, the former chairman of Merck(I believe) took the helm and the stock climbed back to about 11, then traded between 11 and 14. In late May, Option volume increased, news about a discovery concerning muscles was announced, and the stock has risen sharply to Friday, May 24 '96 close of 18.875.

Historically, the stock has failed around 22. Yet AMGEN has more than a 17.7% stake with warrants to increase it's stake to 20%, at 16$ per share. Could this be the time it breaks out?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3508No impact on future sales.DewDiligence_on_SI-May 18
3507REGENERON APPLAUDS SUPREME COURT’S UNANIMOUS OPINION STRIKING DOWN AMGEN’S PCSK9Biotechwantabe-May 18
3506Yes, any we’ll have to wait 2 quarters to find out it 8mg can steam the tide.Biotechwantabe1May 4
3505Looks like the market was correct to worry about Vabysmo, investors.comA.J. Mullen-May 4
3504Lilly’s Alzheimer Results More evidence that clearing the plaque works. Helps Biotechwantabe-May 3
3503Q1 Roche Zabysmo doing well +432. Does it impact Eylea growth? Probably what’s sA.J. Mullen-April 27
3502biopharmadive.com Option articleBiotechwantabe-April 27
3501Vabismo is already selling at a $2B annualized rate. Roche considers Vabismo to DewDiligence_on_SI-April 27
3500Q1 Dupi +40%. Wow Q1 cov2 Roche shipment to Japan +568m. Not expected. Q1 RocheBiotechwantabe-April 27
3499It’s safe and showed reduction of Ab in humans. FDA partial hold seem temporary Biotechwantabe-April 27
3498Thoughts on ALN-APP? investor.regeneron.comFelix B-April 26
3497A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Biotechwantabe-March 29
3496My buddy and his son were very happy with dupixent and had clear skin. Amusinglypheilman_-March 20
3495Regeneron Pharmaceuticals, Inc. Sat, March 18, 2023 at 7:00 AM PDT More than twA.J. Mullen-March 19
34942023 guesstimate Dupi 8.68b +35% +3b Eylea 9.65b (hard to project +/-) 0 LibtaBiotechwantabe-March 1
3493REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESUBiotechwantabe-February 3
3492Thanks for all info. 1H 2023 will be interesting, think.Miljenko Zuanic-January 16
3491I was thinking it was an insurance fund that was out of money, but as you say, iA.J. Mullen-January 13
3490It is all about co-pay assistance. Someone need to pay difference between what iMiljenko Zuanic-January 13
3489You clearly follow closer than I do. The CEO said it was because of a single fuA.J. Mullen-January 11
3488Co-pay story for end-of-year (4Q relative weak sale) is "standard", foMiljenko Zuanic-January 11
3487Did they cover story on Eylea 4Q sale decline blaming Avastin and copay? ThatA.J. Mullen-January 10
3486Did they cover story on Eylea 4Q sale decline blaming Avastin and copay? Every yMiljenko Zuanic-January 10
3485Worth listening to conference call. Nice dip to buy some more. Presentation at Biotechwantabe1January 9
3484He has a number of good points and I appreciate his enthusiasm although I can alFelix B-12/12/2022
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2023 Knight Sac Media.  Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News